Folate-Liposome (PEGylated) (CAT#: CLBD036LY)

Description
Folate-Liposome (PEGylated) is Liposome (PEGylated) with the PEG-Folate group. Folate binding protein (FBP) is an endogenous protein, which shows a very high affinity for folate. An antibody can be tagged by FBP and an immunoliposome can be formed by non-covalent and high affinity interaction between FBP and folate lipid on the surface of the liposomes.
Lipid Composition
Hydrogenated Soy PC, Cholesterol, DSPE-PEG(2000), DSPE-PEG(2000)-Folate
Buffer
PBS
pH
7.4
Storage
Store in dark at +4°C and do not freeze
Size
100 nm
Quantity
2, 5 mL
Download
DataSheet MSDS
FAQs Published Data Customer Reviews Related Sections
  1. What role does folate play in this liposome?

    Folate is used to target folate receptors, which are often overexpressed in certain cancer cells, making it useful for targeted therapy.

  2. How is the internalized folate-Liposome (PEGylated) beneficial for drug delivery?

    Upon endocytosis and exposure to low pH, the reduced affinity between folate and FBP triggers disassembly, facilitating the intracellular release of drugs.

  3. Why is it important to avoid freezing the liposomes?

    Freezing can damage the liposome structure, rendering them ineffective for their intended application.

  4. What are the storage considerations of Folate-Liposome (PEGylated)?

    It should be stored at 4°C and should never be frozen to maintain liposome integrity and stability.

  5. What precautions should be taken when using hydrophobic ligands or peptides with Folate-Liposome (PEGylated)?

    Hydrophobic ligands or peptides should be solubilized in DMSO or DMF, ensuring that the volume does not exceed 5%.

Folate-Liposome (PEGylated)-fig1


Confocal laser scanning microscopy (CLSM) results of Exo and EL in A2780 cells, B16 cells, and CT26 cells.

This article explores the enhanced therapeutic potential of hybrid exosomes loaded with paclitaxel (PTX) for cancer treatment. The researchers designed a tumor-targeted hybrid exosome vesicle (EL) composed of exosomes and folate liposomes for the delivery of PTX. Subsequently, they evaluated its uptake in cancer cells (A2780, B16, and CT26 cells). The results showed that exosomes exhibited a certain level of cellular internalization, while the fusion with folate liposomes significantly enhanced target recognition and uptake capabilities. In this study, folate liposomes were crucial for selectively targeting cancer cells and promoting improved therapeutic efficacy. This targeting strategy highlights the potential of folate liposomes in enhancing treatment outcomes.

Wang, Xuan, et al. "Enhanced Therapeutic Potential of Hybrid Exosomes Loaded with Paclitaxel for Cancer Therapy." International Journal of Molecular Sciences 25.7 (2024): 3645.

Distributed under Open Access license CC BY 4.0, without modification.

  • Highly Effective Receptor Targeting
    The folate receptor targeting has significantly increased the efficacy of our treatments by ensuring more precise delivery to cancer cells.
  • Minimal Side Effects
    The precise targeting has led to minimal side effects in our animal models, highlighting the safety profile of these liposomes.
  • Consistent Results
    We've achieved consistent and reproducible results using Folate-Liposome (PEGylated), which is critical for our research reproducibility.
  • Reliable Conjugation Performance
    The high-affinity interaction between FBP and folate lipid has been consistent and reliable, simplifying our conjugation processes.
  • Excellent Compatibility
    DMSO and DMF compatibility has allowed us to work with various hydrophobic ligands without compromising liposome integrity.

Click the button below to contact us or submit your feedback about this product.

For Research Use Only. Not For Clinical Use

Online Inquiry

Advertisement